Advisor Group’s Cymabay Therapeutics CBAY Stock Holding History

Advisor Group’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$5K	Buy	2,660 +2,292	+623%	+$8.61K	﹤0.01%	4694
2019 Q3	$2K	Hold	368	–	–	﹤0.01%	5018
2019 Q2	$3K	Sell	368 -2,233	-86%	-$25.3K	﹤0.01%	4906
2019 Q1	$35K	Buy	2,601 +1,920	+282%	+$20.4K	﹤0.01%	3634
2018 Q4	$6K	Sell	681 -1,207	-64%	-$11.5K	﹤0.01%	4461
2018 Q3	$20K	Buy	1,888 +363	+24%	+$4.51K	﹤0.01%	3909
2018 Q2	$20K	Buy	1,525 +225	+17%	+$2.82K	﹤0.01%	3727
2018 Q1	$17K	Buy	1,300 +1,000	+333%	+$12.4K	﹤0.01%	3794
2017 Q4	$3K	Buy	+300	New	+$2.56K	﹤0.01%	4599

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Advisor Group's CBAY Position: Q4 2019 in Review

Advisor Group increased its Cymabay Therapeutics (CBAY) stake by 623% in Q4 2019, buying an estimated $8.61K and bringing the position to 2,660 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4694.

Advisor Group first reported a position in CBAY in Q4 2017 and has held it in 9 quarters since. The position peaked at $35K in Q1 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

Advisor Group held 2,660 shares of Cymabay Therapeutics worth $5K as of Q4 2019.
Advisor Group bought 2,292 Cymabay Therapeutics shares in Q4 2019, an estimated $8.61K.
Cymabay Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4694 holding.
Advisor Group first reported a position in Cymabay Therapeutics in Q4 2017 and has held it in 9 quarters since.
Advisor Group's Cymabay Therapeutics position peaked at $35K in Q1 2019.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.